文献速递淋巴瘤

减低剂量全脑放疗作为原发性中枢神经系统淋巴瘤巩固治疗:一项LOC网络研究

Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study.
PubMed 文献 · Blood Adv · 2022-01-01

该回顾性研究从LOC网络数据库筛选2013至2018年29例<60岁、以大剂量甲氨蝶呤为基础化疗后达完全缓解的原发性中枢神经系统淋巴瘤患者,接受23.4 Gy减低剂量全脑放疗巩固。中位随访期间9例(31%)复发,1、2、5年无进展生存率分别为89%、72%、69%,总生存率分别为100%、89%、86%,36个月神经心理随访结果令人鼓舞。

要点

  • 23.4 Gy减低剂量全脑放疗巩固后1、2、5年无进展生存率分别为89%、72%、69%。
  • 1、2、5年总生存率分别为100%、89%、86%,与标准剂量全脑放疗观察值一致。
  • 9例(31%)复发,放疗至复发中位时间8.7个月(四分位距4-11.5)。

核心结论

  • 研究结果结合2期研究结果支持在<60岁诱导治疗后达完全缓解的患者中以减低剂量全脑放疗替代标准剂量全脑放疗作为巩固治疗。
  • 36个月神经心理随访的亚组患者结果令人鼓舞,多数患者维持或改善基线状态。

研究设计与样本

  • 回顾性研究,从LOC网络(眼脑淋巴瘤网络)数据库筛选患者。
  • 纳入2013至2018年诊断的29例<60岁原发性中枢神经系统淋巴瘤患者,均在大剂量甲氨蝶呤为基础化疗后达完全缓解或未确认的完全缓解,并接受减低剂量全脑放疗(23.4 Gy)作为一线巩固治疗。
  • 如有可用数据,报告前瞻性神经心理随访结果。

主要发现

  • 随访期间9例(31%)患者复发,放疗至复发中位时间8.7个月(四分位距4-11.5)。
  • 9例复发患者中5例接受挽救治疗并以强化化疗和自体干细胞移植巩固。
  • 1、2、5年无进展生存率分别为89%(95%CI 79%-100%)、72%(95%CI 56%-88%)、69%(95%CI 52%-85%)。
  • 1、2、5年总生存率分别为100%、89%(95%CI 79%-100%)、86%(95%CI 74%-99%),与标准剂量全脑放疗观察值一致。
  • 未识别出预后因素;亚组患者36个月神经心理随访结果令人鼓舞,多数患者维持或改善基线状态。

关键数值与推荐

  • 减低剂量全脑放疗剂量为23.4 Gy,用于<60岁患者。
  • 完全缓解定义为完全缓解或未确认的完全缓解(原文为complete (CR) or unconfirmed CR)。

临床怎么用

  • 作者认为,研究结果结合2期研究结果支持在<60岁诱导治疗后达完全缓解的患者中以减低剂量全脑放疗替代标准剂量全脑放疗作为巩固治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The optimal consolidation strategy for primary central nervous system lymphoma (PCNSL) remains controversial. Preventing radio-induced neurotoxicity of consolidation treatment through reduced-dose whole-brain radiotherapy (rdWBRT) at a dose of 23.4 Gy is an interesting alternative to conventional WBRT in patients aged <60 years. From the LOC Network (Network for Oculo-cerebral Lymphomas) database, we retrospectively selected patients with PCNSL aged <60 years who showed complete (CR) or unconfirmed CR after high-dose methotrexate-based chemotherapy and had received consolidation rdWBRT as the first-line treatment. If available, prospective neuropsychological follow-ups were reported. Twenty-nine patients diagnosed between 2013 and 2018 met the study selection criteria. Nine (31%) patients experienced relapse during the follow-up, with a median time from radiotherapy to recurrence of 8.7 months (interquartile range, 4-11.5). Five of those patients received salvage treatment and consolidation with intensive chemotherapy and autologous stem cell transplantation. Progression-free survival rates were 89% (95% confidence interval [CI] 79%-100%), 72% (95% CI, 56%-88%), and 69% (95% CI, 52%-85%) at 1, 2, and 5 years, respectively. Overall survival rates were 100%, 89% (95% CI, 79%-100%), and 86% (95% CI, 74%-99%) at 1, 2, and 5 years, respectively, and were consistent with those observed for standard-dose WBRT (sdWBRT). No prognostic factor was identified. The results of the 36-month neuropsychological follow-up for a subset of patients appeared reassuring, with most patients exhibiting maintenance of or improvements in their baseline conditions. Our results, combined with phase 2 study results, support the use of rdWBRT instead of sdWBRT as a consolidation treatment in <60-year-old patients showing CR after induction treatment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lesueur P, Damaj G, Hoang-Xuan K, et al. Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study. Blood Adv. 2022. PMID: 35772168. doi:10.1182/bloodadvances.2022007011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。